Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Refinement of prognostication for IDH-mutant astrocytomas using DNA methylation-based classification.

Brain pathology (Zurich, Switzerland) - 1 Sept 2024

Kling Teresia, Ferreyra Vega Sandra, Suman Medha, Dénes Anna, Lipatnikova Anna, Lagerström Stina, Olsson Bontell Thomas, Jakola Asgeir Store, Carén Helena

Abstract excerpt

The 2021 World Health Organization (WHO) grading system of isocitrate dehydrogenase (IDH)-mutant astrocytomas relies on histological features and the presence of homozygous deletion of the cyclin-dependent kinase inhibitor 2A and 2B (CDKN2A/B). DNA methylation profiling has become highly relevant in the diagnosis of central nervous system (CNS) tumors including gliomas, and it has been incorporated into routine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytoma
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cohort Studies

Share to Cyclin-Dependent Kinase Inhibitor p16

Share to DNA Methylation

Share to Isocitrate Dehydrogenase

Share to Neoplasm Grading

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 38168467
DOI: 10.1111/bpa.13233
PMCID: PMC11328339

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Refinement of prognostication for IDH-mutant astrocytomas using DNA methylation-based classification.PMID 38168467Read ↗

Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas.Semantic proximity Read ↗

Expanding the molecular grading criteria in IDH-mutant astrocytoma.Semantic proximity Read ↗

Molecular and clinical prognostic factors in isocitrate dehydrogenase-mutant astrocytomas: Insights into biomarker-driven stratification.Semantic proximity Read ↗

Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.Semantic proximity Read ↗

Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review.Semantic proximity Read ↗

Canonical amplifications and CDKN2A/B loss refine IDH1/2-mutant astrocytoma prognosisSemantic proximity Read ↗

DNA copy number patterns reveal prognostic markers and elucidate mechanisms of evolution in IDH-mutant astrocytoma.Semantic proximity Read ↗

T2-FLAIR Mismatch Sign Predicts DNA Methylation Subclass and CDKN2A/B Status in IDH-Mutant Astrocytomas.Semantic proximity Read ↗

Novel insight into histological and molecular astrocytoma, IDH-mutant, Grade 4 by the updated WHO classification of central nervous system tumors.Semantic proximity Read ↗

Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma.Semantic proximity Read ↗

CDKN2A mutations have equivalent prognostic significance to homozygous deletion in IDH-mutant astrocytoma.Semantic proximity Read ↗

An Analysis for IDH-Mutant Grade 4 Astrocytoma Based on WHO CNS 5: Implication of Clinical Practice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.